Life and Geneart


Life Technologies has succeeded in buying a majority, 74 per cent stake in Geneart, the German maker of synthetic genes and DNA segments, propelling Life into the nascent synthetic-biology field.

“The burgeoning field of synthetic biology is filled with opportunities where many of Life Technologies’ genomic and sequencing products already play lead roles,” said Gregory Lucier, chairman and CEO of Life Technologies in a statement. “Just as Life Technologies is a pioneer in genetic sequencing, cloning and regenerative medicine, we will be able to directly participate and lead in synthetic biology by offering the tools our customers need to accelerate discoveries in this emerging field.”

About this Entry

This page contains a single entry by Chris Edwards published on June 1, 2010 8:39 PM.

Another day, another ethics initiative was the previous entry in this blog.

Using synthetic biology to design antibiotics is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.